Company Overview: CPRX

Upcoming Projects (CPRX)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (CPRX)

Assessing Catalyst Pharma's AGAMREE (Vamorolone) for Treating Duchenne Muscular Dystrophy, following the recent FDA approval
Tickers: CPRX, SPHDF, SANN.XSWX
Executed On: Nov 17, 2023 at 07:45 AM EST
Legal Alpha: Understanding the patent strength of Catalyst Pharmaceuticals’ Firdapse after Teva’s ANDA challenge
Tickers: CPRX, TEVA
Executed On: Feb 07, 2023 at 02:00 PM EST

Upcoming & Overdue Catalysts (CPRX)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (CPRX)

Catalyst Pharmaceuticals (CPRX) Announces Filing of Patent Infringement Actions Against Jacobus Pharmaceuticals and PantherRx
Ticker: CPRX
Occurred on: Oct 19, 2020
Phase 3 data of Firdapse in Congenital Myasthenic Syndromes (CMS) due 1H 2019
Ticker: CPRX
Occurred on: Oct 30, 2019
PDUFA goal date set for November 28, 2018 for Catalyst Pharma's (CPRX) Firdapse in Lambert-Eaton Myasthenic Syndrome (LEMS)
Ticker: CPRX
Occurred on: Nov 29, 2018
Catalyst Pharmaceuticals (CPRX) planning New Drug Application (NDA) submission for Firdapse, a neuronal potassium channel blocker, in Q1 2018
Ticker: CPRX
Occurred on: Mar 29, 2018
Catalyst Therapeutics (CRPX) se to recommence pre-commercialization activities for Firdapse in second half of 2017, aiming for a possible 2018 relaunch
Ticker: CPRX
Occurred on: Nov 08, 2017
Catalyst Therapeutics (CPRX) Phase 3 trial LMS-003, evaluating the efficacy and safety of Firdapse in patients with Lambert-Eaton Myasthenic syndrome (LEMS), set to complete in second half 2017
Ticker: CPRX
Occurred on: Aug 09, 2017
Catalyst Therapeutics (CRPX) announces topline data from Phase 2/3 trial evaluating Firdapse in treating for patients with MuSK-MG myasthenia gravis
Ticker: CPRX
Occurred on: Mar 15, 2017
Catalyst Pharma (CPRX) Agrees with FDA on Special Protocol Assessment (SPA) for Phase 3 Trial Assessing Firdapse in Lambert-Eaton Myasthenic Syndrome (LEMS)
Ticker: CPRX
Occurred on: Oct 31, 2016
Catalyst Pharmaceuticals Announces Agreement with FDA on Confirmatory Phase 3 Study Protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome
Ticker: CPRX
Occurred on: Jun 13, 2016
FDA requests Catalyst Pharma to conduct a new Phase 3 clinical trial to assess lead product candidate and Orphan Drug- and Breakthrough Therapy-tagged Firdapse (amifampridine phosphate) for the treatment of Lambert-Eaton myasthenic syndrome
Ticker: CPRX
Occurred on: Apr 26, 2016
Catalyst Receives "Refusal to File" Letter from FDA After Incomplete New Drug Application for Firdapse
Ticker: CPRX
Occurred on: Feb 17, 2016
Catalyst Pharmaceuticals Completes NDA Submission to FDA for Firdapse for the Treatment of Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes
Ticker: CPRX
Occurred on: Dec 17, 2015
Catalyst Pharma (CPRX) to Present at Annual BIO Investor Forum
Tickers: CPRX, MNK
Occurred on: Oct 21, 2015

Strategic Initiatives (CPRX)

Catalyst Pharma (CPRX) Announces Collaboration to Offer Biocept's (BIOC) Target Selector Platform in Phase 3 Study Evaluating Firdapse in Patients with Lambert Eaton Myasthenic Syndrome (LEMS)
Tickers: CPRX, BIOC
Announcement Date: Mar 14, 2017

CPRX Overview